LOS ANGELES, Nov. 3, 2025 /PRNewswire/ — Ktrowe Digital Asset Center announced that it has officially obtained the Money Services Business (MSB) license issued by the U.S. Financial Crimes Enforcement Network (FinCEN). This achievement represents a key milestone in the company’s long-term compliance and globalization roadmap, allowing it to legally provide regulated digital asset services… Continue reading Ktrowe Digital Asset Center Obtains U.S. FinCEN MSB License
Tag: Strategy
Savara Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – SVRA
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ — The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. (“Savara ” or “the Company”) (NASDAQ: SVRA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders… Continue reading Savara Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – SVRA
Fly-E Group, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – FLYE
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ — The DJS Law Group reminds investors of a class action lawsuit against Fly-E Group, Inc. (“Fly-E ” or “the Company”) (NASDAQ: FLYE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.… Continue reading Fly-E Group, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – FLYE
PureHealth Delivers Strong 9-Month Results with AED 20.1 Billion in Revenue and AED 1.55 Billion in Net Profit
ABU DHABI, UAE, Nov. 3, 2025 /PRNewswire/ — PureHealth Holding PJSC (“PureHealth” or “the Group”) (ADX: PUREHEALTH), the largest healthcare group in the Middle East, today announced its financial results for the nine-month period ended 30 September 2025. The Group reported revenue of AED 20.1 billion, up 6% year-on-year, reflecting strong performance across both its… Continue reading PureHealth Delivers Strong 9-Month Results with AED 20.1 Billion in Revenue and AED 1.55 Billion in Net Profit
Tronox Holdings plc Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – TROX
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ — The DJS Law Group reminds investors of a class action lawsuit against Tronox Holdings plc (“Tronox” or “the Company”) (NYSE: TROX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders… Continue reading Tronox Holdings plc Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – TROX
bp unlocks value, divests non-controlling interests in US onshore midstream assets for $1.5 billion
bp divests non-controlling interests in Permian and Eagle Ford midstream assets to private investor Sixth Street for $1.5 billion Agreement enables bp to unlock capital from infrastructure, while retaining operatorship and control of strategic midstream assets Transaction delivers a material contribution towards bp’s 2025 expected divestment proceeds and target of $20 billion of divestments by the end… Continue reading bp unlocks value, divests non-controlling interests in US onshore midstream assets for $1.5 billion
ArisGlobal Announces NavaX™ Agents Suite
Orchestrated by the NavaX Super Agent, the Suite includes previously launched MedDRA Coding Agent and upcoming cross-domain Agents BOSTON, Nov. 3, 2025 /PRNewswire/ — ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced the launch of NavaX™ Agents, a major advancement in the company’s AI strategy that brings… Continue reading ArisGlobal Announces NavaX™ Agents Suite
Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease
The European Medicines Agency (EMA) authorises initiation of a Phase IIa study evaluating AT-001 in patients diagnosed with Alzheimer’s disease EMA grants Orphan Drug Designation (ODD) to AT-001 for hereditary cystatin C amyloid angiopathy (HCCAA), a rare familial dementia REYKJAVÍK, Iceland, Nov. 3, 2025 /PRNewswire/ — Arctic Therapeutics (ATx), an Iceland-based clinical-stage biopharmaceutical company, today announced… Continue reading Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease
Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease
The European Medicines Agency (EMA) authorises initiation of a Phase IIa study evaluating AT-001 in patients diagnosed with Alzheimer’s disease EMA grants Orphan Drug Designation (ODD) to AT-001 for hereditary cystatin C amyloid angiopathy (HCCAA), a rare familial dementia REYKJAVÍK, Iceland, Nov. 3, 2025 /PRNewswire/ — Arctic Therapeutics (ATx), an Iceland-based clinical-stage biopharmaceutical company, today announced… Continue reading Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease
Omni Bridgeway Delivers Strong 1Q26 Performance and Strategic Momentum
SYDNEY, Nov. 3, 2025 /PRNewswire/ — Omni Bridgeway Limited (ASX: OBL), a global leader in legal asset management, today announced strong results for the first quarter of FY26, underscoring continued execution of its growth strategy and operational discipline. Key Highlights Income Growth: A strong quarter delivering A$136 million in cash investment proceeds, achieving a 2.8x MOIC… Continue reading Omni Bridgeway Delivers Strong 1Q26 Performance and Strategic Momentum